Safety and efficiency of modified-VMP schedule for patients with multiple myeloma who are not eligible for high-dose chemotherapy supported with autologous stem-cell trasplantation

Trial Profile

Safety and efficiency of modified-VMP schedule for patients with multiple myeloma who are not eligible for high-dose chemotherapy supported with autologous stem-cell trasplantation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Bortezomib (Primary) ; Melphalan (Primary) ; Prednisolone (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms OMSG-2
  • Most Recent Events

    • 22 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top